Bharat Shimpukade

Bharat Shimpukade

Auto-generated profile, based on publicly available information

Bharat Shimpukade

Department of Physics, Chemistry and Pharmacy, University of Southern Denmark , Campusvej 55, DK-5230 Odense M, Denmark

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2016 in Chemical Reviews
Verified
Journal Article
Open access
GMGraeme Milligan
Graeme Milligan
BSBharat Shimpukade
Bharat Shimpukade
TUTrond Ulven
Trond Ulven
BHBrian Hudson
Brian Hudson
G protein-coupled receptors (GPCRs) are historically the most successful family of drug targets. In recent times it has become clear that the pharmacology of these receptors is far more complex than previously imagined. Understanding of the pharmacological regulation of GPCRs now extends beyond simple competitive agonism or antagonism by ligands interacting with the orthosteric binding site of the receptor to incorporate concepts of allosteric agonism, allosteric modulation, signaling bias, constitutive activity, and inverse agonism. Herein, we consider how evolving concepts of GPCR pharmacology have shaped understanding of the complex pharmacology of receptors that recognize and are activated by nonesterified or “free” fatty acids (FFAs). The FFA family of receptors is a recently deorphanized set of GPCRs, the members of which are now receiving substantial interest as novel targets for the treatment of metabolic and inflammatory diseases. Further understanding of the complex pharmacology of these receptors will be critical to unlocking their ultimate therapeutic potential.

1 November 2013 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
BHBrian Hudson
Brian Hudson
BSBharat Shimpukade
Bharat Shimpukade
AMAmanda E. Mackenzie
Amanda E. Mackenzie
ABAdrian J. Butcher
Adrian J. Butcher
JPJohn D. Pediani
John D. Pediani
GMGraeme Milligan
Graeme Milligan
TUG-891 [3-(4-((4-fluoro-4′-methyl-[1,1′-biphenyl]-2-yl)methoxy)phenyl)propanoic acid] was recently described as a potent and selective agonist for the long chain free fatty acid (LCFA) receptor 4 (FFA4; previously G protein–coupled receptor 120, or GPR120). Herein, we have used TUG-891 to further define the function of FFA4 and used this compound in proof of principle studies to indicate the therapeutic potential of this receptor. TUG-891 displayed similar signaling properties to the LCFA α-linolenic acid at human FFA4 across various assay end points, including stimulation of Ca2+ mobilization, β-arrestin-1 and β-arrestin-2 recruitment, and extracellular signal-regulated kinase phosphorylation. Activation of human FFA4 by TUG-891 also resulted in rapid phosphorylation and internalization of the receptor. While these latter events were associated with desensitization of the FFA4 signaling response, removal of TUG-891 allowed both rapid recycling of FFA4 back to the cell surface and resensitization of the FFA4 Ca2+ signaling response. TUG-891 was also a potent agonist of mouse FFA4, but it showed only limited selectivity over mouse FFA1, complicating its use in vivo in this species. Pharmacologic dissection of responses to TUG-891 in model murine cell systems indicated that activation of FFA4 was able to mimic many potentially beneficial therapeutic properties previously reported for LCFAs, including stimulating glucagon-like peptide-1 secretion from enteroendocrine cells, enhancing glucose uptake in 3T3-L1 adipocytes, and inhibiting release of proinflammatory mediators from RAW264.7 macrophages, which suggests promise for FFA4 as a therapeutic target for type 2 diabetes and obesity. Together, these results demonstrate both potential but also significant challenges that still need to be overcome to therapeutically target FFA4.

2 May 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BSBharat Shimpukade
Bharat Shimpukade
BHBrian Hudson
Brian Hudson
CHChristine Kiel Hovgaard
Christine Kiel Hovgaard
GMGraeme Milligan
Graeme Milligan
TUTrond Ulven
Trond Ulven

17 January 2018 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
MSMaaike Schilperoort
Maaike Schilperoort
ADAndrea D van Dam
Andrea D van Dam
GHGeerte Hoeke
Geerte Hoeke
ISIrina G. Shabalina
Irina G. Shabalina
AOAnthony Okolo
Anthony Okolo
Mark ChristianMark Christian
Mark Christian
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

22 September 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CACarlos M. G. Azevedo
Carlos M. G. Azevedo
KWKenneth R. Watterson
Kenneth R. Watterson
EWEd T. Wargent
Ed T. Wargent
SHSteffen V. F. Hansen
Steffen V. F. Hansen
BHBrian Hudson
Brian Hudson
TUTrond Ulven
Trond Ulven

1 June 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ABAdrian J. Butcher
Adrian J. Butcher
BHBrian Hudson
Brian Hudson
BSBharat Shimpukade
Bharat Shimpukade
EAElisa Alvarez-Curto
Elisa Alvarez-Curto
RPRudi Prihandoko
Rudi Prihandoko
ATAndrew B. Tobin
Andrew B. Tobin
In addition to being nutrients, free fatty acids act as signaling molecules by activating a family of G protein-coupled receptors. Among these is FFA4, previously called GPR120, which responds to medium and long chain fatty acids, including health-promoting ω-3 fatty acids, which have been implicated in the regulation of metabolic and inflammatory responses. Here we show, using mass spectrometry, mutagenesis, and phosphospecific antibodies, that agonist-regulated phosphorylation of the human FFA4 receptor occurred primarily at five residues (Thr347, Thr349, Ser350, Ser357, and Ser360) in the C-terminal tail. Mutation of these residues reduced both the efficacy and potency of ligand-mediated arrestin-3 recruitment as well as affecting recruitment kinetics. Combined mutagenesis of all five of these residues was insufficient to fully abrogate interaction with arrestin-3, but further mutagenesis of negatively charged residues revealed additional structural components for the interaction with arrestin-3 within the C-terminal tail of the receptor. These elements consist of the acidic residues Glu341, Asp348, and Asp355 located close to the phosphorylation sites. Receptor phosphorylation thus operates in concert with structural elements within the C-terminal tail of FFA4 to allow for the recruitment of arrestin-3. Importantly, these mechanisms of arrestin-3 recruitment operate independently from Gq/11 coupling, thereby offering the possibility that ligands showing stimulus bias could be developed that exploit these differential coupling mechanisms. Furthermore, this provides a strategy for the design of biased receptors to probe physiologically relevant signaling.